Chemometec rolls out future sales hope - starting with American biotech incubators

Chemometec and CEO Michael Eising have launched and sold the first unit of cell counter NC-202, which is an upgrade of the company's best-selling product. The firm is starting sales at brand new biotech companies.

Michael Eising, CEO of Chemometec. Photo: PR / Chemometec

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles